Marksans Pharma - Audited Financial Results for Mar 31, 2009
Marksans Pharma Ltd has informed BSE about the Audited Standalone & Consolidated financial results for the Year ended March 31, 2009.29-06-2009
29-06-2009
Marksans Pharma - Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Marksans Pharma Ltd has submitted the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:08-06-2009
Marksans Pharma - Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Mark Saldanha has submitted the disclosure under Regulation 13(4) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:08-06-2009
Marksans Pharma - Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Marksans Pharma Ltd has submitted the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:05-06-2009
Marksans Pharma - Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Mark Saldanha has submitted the disclosure under Regulation 13(4) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:05-06-2009
Marksans Pharma - FY 09 results by Jun 30, 2009
Marksans Pharma Ltd has informed BSE that the Company will publish Annual Audited Results for the year ended March 31, 2009 before June 30, 2009. Therefore, unaudited financial results for the quarter ended on March 31, 2009 will not be published.21-04-2009
Marksans Pharma - Limited Review for the quarter ended Dec 31, 2008
Marksans Pharma Ltd has informed BSE that the auditor's have conducted the limited review of the unaudited financial results for the quarter ended December 31, 2008.02-03-2009
Marksans Pharma - Unaudited Financial Results for Dec 31, 2008
Marksans Pharma Ltd has informed BSE about the unaudited financial results for the Quarter ended December 31, 2008.31-01-2009
Marksans Pharma - Limited Review for the quarter ended Sep 30, 2008
Marksans Pharma Ltd has informed BSE that the auditor's have conducted the limited review of the unaudited financial results for the quarter ended September 30, 2008.02-12-2008
Marksans Pharma - Certificate of suitability for Ranitidine Hydrochloride
Marksans Pharma Ltd has informed BSE that the Company has received Certificate of suitability for Ranitidine Hydrochloride drug substance from the European Directorate for the Quality of Medicines and Healthcare (EDQM).With the grant of this Certificate of Suitability for Ranitidine Hydrochloride drug substance by EDQM, the doors of European markets have opened for access for the Company's API business....03-11-2008